2025 Q3 -tulosraportti
67 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
29
Myynti
Määrä
284
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 29 | NON | AVA | ||
| 102 | NON | NON | ||
| 25 | NON | NON | ||
| 25 | NON | NRD | ||
| 315 | NON | NRD |
Ylin
16,6VWAP
Alin
14,2VaihtoMäärä
2,4 152 039
VWAP
Ylin
16,6Alin
14,2VaihtoMäärä
2,4 152 039
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 17 733 | 1 906 | +15 827 | 0 |
| Nordnet Bank AB | 111 291 | 108 246 | +3 045 | 79 107 |
| Danske Bank A/S | 13 033 | 15 169 | −2 136 | 0 |
| SSW Market Making GmbH | 5 238 | 9 953 | −4 715 | 0 |
| Avanza Bank AB | 4 744 | 16 765 | −12 021 | 15 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 4 744 | 16 765 | −12 021 | 15 |
| SSW Market Making GmbH | 5 238 | 9 953 | −4 715 | 0 |
| Danske Bank A/S | 13 033 | 15 169 | −2 136 | 0 |
| Nordnet Bank AB | 111 291 | 108 246 | +3 045 | 79 107 |
| Nordea Bank Abp | 17 733 | 1 906 | +15 827 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·7 t sittenHave my largest position in Curasight, but also have e.g. FluoGuide, Dicot Pharma, Cassatech and Xspray Pharma. All somewhat in the same risk group and industry. But am looking to spread myself even further out and am looking for similar opportunities. That is, medico/pharma companies that are in the early phase or that are facing success/failure (failure is always a real risk for these startup companies) Do you have shares in other companies that could be interesting to look at? Not looking for buy recommendations but more stock inspiration. Is not directly Curasight relevant but it seems there are many in this stock who delve into the case and perhaps therefore also know about other opportunities.
·11 t sittenSoon 4000 owners on Nordnet.
·1 päivä sittenSome are enjoying themselves, and playing with fire ;-)
·1 päivä sittenNow we'll have to see if it's even done falling here in February. But I doubt it. 15-19 could well be a range where one can see it dancing up and down and up and down for the next 3 weeks. Unless one has bought in with a horizon of a few weeks, then one should not let oneself be scared by it.
·1 päivä sittenhttps://curasight-pan-cancer-theranostic-platform-at-pre-validation-pri.tiiny.site/ A good write-up about the case, seen in curasight's Discord: https://discord.gg/XcsdMTJQtK Not written by me.
·2 päivää sitten · MuokattuLet me reiterate: There is no guarantee that this case will result in a sale or a major strategic partnership agreement! But the point is that when one looks at what Curasight is actually involved in, there is a significant discrepancy between the company's real position and the current share price. This asymmetry arises not only in one place, but across several key areas, which are largely not reflected in today's share price. Where does the case significantly deviate from today's share price: 1) Clinical position: Curasight is traded as “early biotech”, even though uPAR is already validated in hundreds of patients via uTRACE. Target risk is significantly reduced before therapy is complete. 2) Pipeline logic - The market sees one Phase I study. - The case is in practice diagnostics + therapy + basket strategy – i.e., platform, not single-asset. 3) IP and option value: Gen 2 uPAR and radionuclide extensions prolong exclusivity and increase option value. 4) Partner validation: Curium reduces CMC, supply chain, and regulatory risk, but the market prices the company as if these risks are still the same as before (Curium agreement = share price 9) 5) NDA asymmetry: Significant information is known under NDA, not public. Absence of news is therefore not equal to absence of progress. 6) Strategic optionality: The share price reflects the next data point – not strategic outcomes like partnership, basket, or sale. Boiled down to a bouillon cube Curasight deviates not only in one place, but across several key value drivers, which cannot – or must not – yet be reflected in the share price. This naturally does not guarantee a specific price/outcome, but it explains why today's share price can be a poor measure of the company's real value. It is precisely this asymmetry that I have been working with lately: Trying to understand where, how, and why the deviations arise – and with the help of AI, attempting to uncover and quantify the underlying values, based on empirical data, comparable cases (RayzeBio et al.) and observable behavior patterns in both Big Pharma and Top 3 in Curasight. ------------------------------------------------------------ 1. The asymmetry is structural – not temporary It is due to: • NDA • ownership structure • timing in relation to clinic and strategy → not “lack of interest” or “inefficiency”. B. The share price is a distribution question – not a value question The current share price determines who gets how much of the value, - but not IF it exists. The value is only realized by: • strategic agreement • transaction • or significant de-risking (e.g., basket). I hope this clarifies some of the questions raised in the forum. And no, I do not disclose my portfolios, for which one should I choose? They serve different purposes each. Would it bring credibility if I showed my newly created ASK portfolio that is maxed out with Curasight at share price 12,40, when I moved it over from DDB to avoid paying 27 % in tax (42-15), when Curasight is sold? All right then 😉
·2 päivää sittenYou will naturally pay tax on the return from your normal brokerage account when you sell them in 2026.. E.g., bought at 9 sold at 16 = 7,- per share, 27% is paid on the first 79,400 (2026) and 42% on your profit above that. But on your share savings account you only pay 17% of your subsequent profit. Assuming you currently have a profit of 100k, it can still be worthwhile to transfer them. Let's just assume, for example, that in half a year you have an additional 500,000 in profit. 17% of 500,000 instead of 42%.....easy math.... 😉
·1 päivä sitten@Geroda @AllanL Another good idea to contact your bank; I have my ASK with Danske Bank and after the latest rectified issue, in December they incorrectly marked a checkbox for Curasight, so the company appeared as unlisted (!!! jeesus!!); I had to convince DB that the company had not been delisted, before they opened up again...this meant, among other things, that I could not sell/buy curasight for a couple of days before the error was corrected.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
67 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 t sittenHave my largest position in Curasight, but also have e.g. FluoGuide, Dicot Pharma, Cassatech and Xspray Pharma. All somewhat in the same risk group and industry. But am looking to spread myself even further out and am looking for similar opportunities. That is, medico/pharma companies that are in the early phase or that are facing success/failure (failure is always a real risk for these startup companies) Do you have shares in other companies that could be interesting to look at? Not looking for buy recommendations but more stock inspiration. Is not directly Curasight relevant but it seems there are many in this stock who delve into the case and perhaps therefore also know about other opportunities.
- ·11 t sittenSoon 4000 owners on Nordnet.
- ·1 päivä sittenSome are enjoying themselves, and playing with fire ;-)·1 päivä sittenNow we'll have to see if it's even done falling here in February. But I doubt it. 15-19 could well be a range where one can see it dancing up and down and up and down for the next 3 weeks. Unless one has bought in with a horizon of a few weeks, then one should not let oneself be scared by it.
- ·1 päivä sittenhttps://curasight-pan-cancer-theranostic-platform-at-pre-validation-pri.tiiny.site/ A good write-up about the case, seen in curasight's Discord: https://discord.gg/XcsdMTJQtK Not written by me.
- ·2 päivää sitten · MuokattuLet me reiterate: There is no guarantee that this case will result in a sale or a major strategic partnership agreement! But the point is that when one looks at what Curasight is actually involved in, there is a significant discrepancy between the company's real position and the current share price. This asymmetry arises not only in one place, but across several key areas, which are largely not reflected in today's share price. Where does the case significantly deviate from today's share price: 1) Clinical position: Curasight is traded as “early biotech”, even though uPAR is already validated in hundreds of patients via uTRACE. Target risk is significantly reduced before therapy is complete. 2) Pipeline logic - The market sees one Phase I study. - The case is in practice diagnostics + therapy + basket strategy – i.e., platform, not single-asset. 3) IP and option value: Gen 2 uPAR and radionuclide extensions prolong exclusivity and increase option value. 4) Partner validation: Curium reduces CMC, supply chain, and regulatory risk, but the market prices the company as if these risks are still the same as before (Curium agreement = share price 9) 5) NDA asymmetry: Significant information is known under NDA, not public. Absence of news is therefore not equal to absence of progress. 6) Strategic optionality: The share price reflects the next data point – not strategic outcomes like partnership, basket, or sale. Boiled down to a bouillon cube Curasight deviates not only in one place, but across several key value drivers, which cannot – or must not – yet be reflected in the share price. This naturally does not guarantee a specific price/outcome, but it explains why today's share price can be a poor measure of the company's real value. It is precisely this asymmetry that I have been working with lately: Trying to understand where, how, and why the deviations arise – and with the help of AI, attempting to uncover and quantify the underlying values, based on empirical data, comparable cases (RayzeBio et al.) and observable behavior patterns in both Big Pharma and Top 3 in Curasight. ------------------------------------------------------------ 1. The asymmetry is structural – not temporary It is due to: • NDA • ownership structure • timing in relation to clinic and strategy → not “lack of interest” or “inefficiency”. B. The share price is a distribution question – not a value question The current share price determines who gets how much of the value, - but not IF it exists. The value is only realized by: • strategic agreement • transaction • or significant de-risking (e.g., basket). I hope this clarifies some of the questions raised in the forum. And no, I do not disclose my portfolios, for which one should I choose? They serve different purposes each. Would it bring credibility if I showed my newly created ASK portfolio that is maxed out with Curasight at share price 12,40, when I moved it over from DDB to avoid paying 27 % in tax (42-15), when Curasight is sold? All right then 😉·2 päivää sittenYou will naturally pay tax on the return from your normal brokerage account when you sell them in 2026.. E.g., bought at 9 sold at 16 = 7,- per share, 27% is paid on the first 79,400 (2026) and 42% on your profit above that. But on your share savings account you only pay 17% of your subsequent profit. Assuming you currently have a profit of 100k, it can still be worthwhile to transfer them. Let's just assume, for example, that in half a year you have an additional 500,000 in profit. 17% of 500,000 instead of 42%.....easy math.... 😉·1 päivä sitten@Geroda @AllanL Another good idea to contact your bank; I have my ASK with Danske Bank and after the latest rectified issue, in December they incorrectly marked a checkbox for Curasight, so the company appeared as unlisted (!!! jeesus!!); I had to convince DB that the company had not been delisted, before they opened up again...this meant, among other things, that I could not sell/buy curasight for a couple of days before the error was corrected.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
29
Myynti
Määrä
284
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 29 | NON | AVA | ||
| 102 | NON | NON | ||
| 25 | NON | NON | ||
| 25 | NON | NRD | ||
| 315 | NON | NRD |
Ylin
16,6VWAP
Alin
14,2VaihtoMäärä
2,4 152 039
VWAP
Ylin
16,6Alin
14,2VaihtoMäärä
2,4 152 039
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 17 733 | 1 906 | +15 827 | 0 |
| Nordnet Bank AB | 111 291 | 108 246 | +3 045 | 79 107 |
| Danske Bank A/S | 13 033 | 15 169 | −2 136 | 0 |
| SSW Market Making GmbH | 5 238 | 9 953 | −4 715 | 0 |
| Avanza Bank AB | 4 744 | 16 765 | −12 021 | 15 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 4 744 | 16 765 | −12 021 | 15 |
| SSW Market Making GmbH | 5 238 | 9 953 | −4 715 | 0 |
| Danske Bank A/S | 13 033 | 15 169 | −2 136 | 0 |
| Nordnet Bank AB | 111 291 | 108 246 | +3 045 | 79 107 |
| Nordea Bank Abp | 17 733 | 1 906 | +15 827 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
2025 Q3 -tulosraportti
67 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 t sittenHave my largest position in Curasight, but also have e.g. FluoGuide, Dicot Pharma, Cassatech and Xspray Pharma. All somewhat in the same risk group and industry. But am looking to spread myself even further out and am looking for similar opportunities. That is, medico/pharma companies that are in the early phase or that are facing success/failure (failure is always a real risk for these startup companies) Do you have shares in other companies that could be interesting to look at? Not looking for buy recommendations but more stock inspiration. Is not directly Curasight relevant but it seems there are many in this stock who delve into the case and perhaps therefore also know about other opportunities.
- ·11 t sittenSoon 4000 owners on Nordnet.
- ·1 päivä sittenSome are enjoying themselves, and playing with fire ;-)·1 päivä sittenNow we'll have to see if it's even done falling here in February. But I doubt it. 15-19 could well be a range where one can see it dancing up and down and up and down for the next 3 weeks. Unless one has bought in with a horizon of a few weeks, then one should not let oneself be scared by it.
- ·1 päivä sittenhttps://curasight-pan-cancer-theranostic-platform-at-pre-validation-pri.tiiny.site/ A good write-up about the case, seen in curasight's Discord: https://discord.gg/XcsdMTJQtK Not written by me.
- ·2 päivää sitten · MuokattuLet me reiterate: There is no guarantee that this case will result in a sale or a major strategic partnership agreement! But the point is that when one looks at what Curasight is actually involved in, there is a significant discrepancy between the company's real position and the current share price. This asymmetry arises not only in one place, but across several key areas, which are largely not reflected in today's share price. Where does the case significantly deviate from today's share price: 1) Clinical position: Curasight is traded as “early biotech”, even though uPAR is already validated in hundreds of patients via uTRACE. Target risk is significantly reduced before therapy is complete. 2) Pipeline logic - The market sees one Phase I study. - The case is in practice diagnostics + therapy + basket strategy – i.e., platform, not single-asset. 3) IP and option value: Gen 2 uPAR and radionuclide extensions prolong exclusivity and increase option value. 4) Partner validation: Curium reduces CMC, supply chain, and regulatory risk, but the market prices the company as if these risks are still the same as before (Curium agreement = share price 9) 5) NDA asymmetry: Significant information is known under NDA, not public. Absence of news is therefore not equal to absence of progress. 6) Strategic optionality: The share price reflects the next data point – not strategic outcomes like partnership, basket, or sale. Boiled down to a bouillon cube Curasight deviates not only in one place, but across several key value drivers, which cannot – or must not – yet be reflected in the share price. This naturally does not guarantee a specific price/outcome, but it explains why today's share price can be a poor measure of the company's real value. It is precisely this asymmetry that I have been working with lately: Trying to understand where, how, and why the deviations arise – and with the help of AI, attempting to uncover and quantify the underlying values, based on empirical data, comparable cases (RayzeBio et al.) and observable behavior patterns in both Big Pharma and Top 3 in Curasight. ------------------------------------------------------------ 1. The asymmetry is structural – not temporary It is due to: • NDA • ownership structure • timing in relation to clinic and strategy → not “lack of interest” or “inefficiency”. B. The share price is a distribution question – not a value question The current share price determines who gets how much of the value, - but not IF it exists. The value is only realized by: • strategic agreement • transaction • or significant de-risking (e.g., basket). I hope this clarifies some of the questions raised in the forum. And no, I do not disclose my portfolios, for which one should I choose? They serve different purposes each. Would it bring credibility if I showed my newly created ASK portfolio that is maxed out with Curasight at share price 12,40, when I moved it over from DDB to avoid paying 27 % in tax (42-15), when Curasight is sold? All right then 😉·2 päivää sittenYou will naturally pay tax on the return from your normal brokerage account when you sell them in 2026.. E.g., bought at 9 sold at 16 = 7,- per share, 27% is paid on the first 79,400 (2026) and 42% on your profit above that. But on your share savings account you only pay 17% of your subsequent profit. Assuming you currently have a profit of 100k, it can still be worthwhile to transfer them. Let's just assume, for example, that in half a year you have an additional 500,000 in profit. 17% of 500,000 instead of 42%.....easy math.... 😉·1 päivä sitten@Geroda @AllanL Another good idea to contact your bank; I have my ASK with Danske Bank and after the latest rectified issue, in December they incorrectly marked a checkbox for Curasight, so the company appeared as unlisted (!!! jeesus!!); I had to convince DB that the company had not been delisted, before they opened up again...this meant, among other things, that I could not sell/buy curasight for a couple of days before the error was corrected.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
29
Myynti
Määrä
284
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 29 | NON | AVA | ||
| 102 | NON | NON | ||
| 25 | NON | NON | ||
| 25 | NON | NRD | ||
| 315 | NON | NRD |
Ylin
16,6VWAP
Alin
14,2VaihtoMäärä
2,4 152 039
VWAP
Ylin
16,6Alin
14,2VaihtoMäärä
2,4 152 039
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 17 733 | 1 906 | +15 827 | 0 |
| Nordnet Bank AB | 111 291 | 108 246 | +3 045 | 79 107 |
| Danske Bank A/S | 13 033 | 15 169 | −2 136 | 0 |
| SSW Market Making GmbH | 5 238 | 9 953 | −4 715 | 0 |
| Avanza Bank AB | 4 744 | 16 765 | −12 021 | 15 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 4 744 | 16 765 | −12 021 | 15 |
| SSW Market Making GmbH | 5 238 | 9 953 | −4 715 | 0 |
| Danske Bank A/S | 13 033 | 15 169 | −2 136 | 0 |
| Nordnet Bank AB | 111 291 | 108 246 | +3 045 | 79 107 |
| Nordea Bank Abp | 17 733 | 1 906 | +15 827 | 0 |